Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

116
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
116
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

123
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
123

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

MAD-MT Score: A Tool to Optimize Patient Selection for Mechanical Thrombectomy in Distal Vessel Occlusions.

Stroke·2026
Same author

Anterior cerebral artery variants and their influence on endovascular outcomes: a propensity score matched analysis from the CRETA registry.

Neuroradiology·2026
Same author

Middle meningeal artery embolization for chronic subdural hematoma: the role of timing and baseline hematoma volume.

Neuroradiology·2026
Same author

CT Quantification of Intraventricular Hemorrhage Volume in Poor-Grade Aneurysmal Subarachnoid Hemorrhage: Impact on Mortality and Long-Term Disability.

Neurocritical care·2026
Same author

Bridging therapy versus mechanical thrombectomy alone in patients with basilar artery occlusion and mild symptoms: a retrospective observational study.

Journal of neurology·2026
Same author

Interaction of Intraprocedural Antiplatelets and Intravenous Thrombolysis in Acute Intracranial Stenting: RESISTANT Registry Subanalysis.

Annals of clinical and translational neurology·2026

相关实验视频

Updated: Jun 8, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K

在活跃的性结肠炎中,risankizumab诱导并维持了缓解.

Alessandro Pedicelli1, Waqqas Afif1

  • 1McGill University, Montreal, Quebec, Canada (A.P., W.A.).

Annals of internal medicine
|November 4, 2024
PubMed
概括

在两项临床试验中,risankizumab有效治疗中度至严重的性结肠炎. 患者实现了临床缓解和内镜改善,展示了其治疗潜力.

科学领域:

  • 胃肠病学和肝病学
  • 免疫学 免疫学 免疫学
  • 临床试验 临床试验

背景情况:

  • 性结肠炎 (UC) 是一种慢性炎症性肠病,具有显著的未满足需求.
  • 目前针对UC的治疗方法在有效性和安全性方面存在局限性.
  • 新的治疗目标对于改善患者的治疗结果至关重要.

研究的目的:

  • 评估瑞桑基祖马布在中度至重度性结肠炎患者的疗效和安全性.
  • 为了评估临床缓解和内镜愈合与risankizumab治疗.
  • 为了在随机对照试验中比较瑞桑基祖马布与安慰剂的性能.

主要方法:

  • 进行了两项3期随机,双盲,安慰剂对照试验 (INSPIRE和COMMAND).
  • 纳入了中度至重度活跃性结肠炎的成年患者.
  • 患者接受了静脉注射瑞桑基祖马布诱导,随后进行皮下维持疗法或安慰剂.

主要成果:

  • 与安慰剂相比,risankizumab在52周的临床缓解率在统计学上显著地更高.
  • 在RISANKIZUMAB组,内镜改善显著增加.
  • 在risankizumab和安慰剂组之间,不良事件概况是可比的,没有发现新的安全问题.

更多相关视频

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

822
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.5K

相关实验视频

Last Updated: Jun 8, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

822
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.5K

结论:

  • 瑞桑基祖马布是中度至重度性结肠炎的有效和安全治疗选择.
  • 该药物为UC患者提供了一个有前途的新治疗途径.
  • 长期数据将进一步阐明瑞桑基祖马布的持续疗效和安全性.